

18 November 2021

## TRADING UPDATE: RESULTS FOR 4 MONTHS TO OCTOBER 2021

Sonic Healthcare (ASX: SHL; ADR: SKHHY) continues to support governments, healthcare authorities and communities with COVID-19 pandemic control initiatives in its seven countries of operation.

Sonic's staff perform crucial frontline roles in combating the pandemic, with its laboratories testing tens of thousands of people every day for COVID-19 (~36 million COVID-19 PCR tests performed in total to date), as well as conducting COVID-19 serology testing and, in some markets, COVID-19 whole genome sequencing to aid identification of variants. In Australia Sonic has provided more than 1 million COVID-19 vaccinations to the community through special purpose high volume hubs and through its network of more than 200 medical centres.

In addition to these COVID-19 specific services, Sonic's businesses continue to seamlessly provide high quality essential non-COVID healthcare services for hundreds of thousands of patients every day, despite the operational challenges posed by the pandemic.

Headline financial results for the four months to 31 October 2021 ('YTD Oct 2021') are presented below.

A\$M	YTD Oct 2021	YTD Oct 2020	Growth
<b>Revenue</b>	3,087	2,942	5%
<b>EBITDA</b>	991	853	16%

Notes:

- EBITDA = Earnings before interest, tax, depreciation and amortisation
- Actual average currency exchange rates used in both periods
- Prior period impacted by provision for repayment of US\$26 million COVID grant
- Based on unaudited management financial reports

Base business (excluding COVID-19 related services) revenues grew by 6% versus the equivalent period in FY2021, and 4% versus the equivalent period in FY2020 (pre-pandemic), with the comparative periods normalised for currency exchange rates, acquisitions and disposals of businesses, and working days. Base business performance in both the current period and prior year was augmented by substantial volumes of COVID-19 testing.

Sonic has not provided earnings guidance for FY2022 due to COVID-19 related unpredictability. The pandemic continues to cause fluctuations in both COVID-19 testing revenues and, to a lesser extent, the base business. Sonic's base business has become increasingly resilient to impacts of pandemic waves and benefits from the essential nature of its services, as well as geographical and business diversification. The underlying growth drivers for healthcare services remain unchanged.

Sonic's CEO, Dr Colin Goldschmidt, said: "Sonic's 38,000 staff around the world continue to display courage, dedication, initiative and flexibility in meeting the challenges that arise every day in combating the COVID-19 pandemic whilst assisting with the underlying health and well-being of millions of patients. Our Medical Leadership culture continues to provide the guiding light and binding force for our people. I wish to thank every one of our staff for the contributions they have made and continue to make each day as we navigate our way through the pandemic.

"In addition to the heroic efforts of our staff, our response to the pandemic has been enabled by the decades of investment the company has made in infrastructure, equipment and systems. Without this strong base our current outstanding operational and financial performance would not be possible."

This announcement has been authorised by Sonic Healthcare's Board of Directors. For further information regarding this announcement, please contact:

**Dr Colin Goldschmidt**  
CEO  
Sonic Healthcare

Telephone: +61 2 9855 5333  
Email: [colgold@msn.com.au](mailto:colgold@msn.com.au)

**Chris Wilks**  
CFO  
Sonic Healthcare

Telephone: +61 2 9855 5404  
Email: [cdwilks@bigpond.com](mailto:cdwilks@bigpond.com)